China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma
--Phase III trial will evaluate progression-free survival and overall survival of patients with recurrent glioblastoma
--Glioblastoma has an incidence rate of approximately 2.85 to 4.56 per 100,000 population per year in China, suggesting approximately 40,000 to 64,000 new cases of glioblastoma per year. More than 90% glioblastoma patients will relapse after surgery, radiation and chemotherapies
--This is the first Phase III trial of ASC40 as a first-in-class drug candidate targeting tumor lipid metabolism
--Phase II data of patients with recurrent glioblastoma have shown that the overall response rate for ASC40 plus Bevacizumab treatment was 65% including a complete response of 20% and a partial response of 45%